VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma

The addition of cytotoxic drugs to high-dose melphalan as a preparative regimen for autologous stem cell transplantation in multiple myeloma has not resulted in superior activity. Although novel agents have significantly improved outcome in multiple myeloma, their role in preparative regimens remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Nadiminti, Kalyan, Singh Abbi, Kamal Kant, Mott, Sarah L, Dozeman, Lindsay, Tricot, Annick, Schultz, Allyson, Behrends, Sonya, Zhan, Fenghuang, Tricot, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5229169/
https://www.ncbi.nlm.nih.gov/pubmed/28123303
http://dx.doi.org/10.2147/OTT.S112423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5229169/
https://www.ncbi.nlm.nih.gov/pubmed/28123303
http://dx.doi.org/10.2147/OTT.S112423

Ejemplares similares